By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


ChemGenex Pharmaceuticals Limited 

1 Pigdon's Road

Waurn Pond  Victoria  3217  Australia
Phone: 61-3-5227-2752 Fax: 61-3-5227-1322

ChemGenex Pharmaceuticals is a gene-based pharmaceutical development company dedicated to improving the lives of patients by developing novel protein, antibody and small molecule therapeutics in the areas of oncology, obesity, diabetes and central nervous system disorders. The company was formed in 2004 from the merger of AGT Biosciences of Melbourne, Australia and privately held ChemGenex Therapeutics, Inc. of Menlo Park, California.

The ChemGenex pipeline of therapeutics is based on internally discovered targets that play a role in important mechanisms underlying metabolic and CNS diseases coupled with later-stage small molecules in clinical development for the treatment of cancer. The company uses genomic tools such as patient genotyping in clinical development to reduce clinical risk and improve patient outcomes.

ChemGenex has assembled a comprehensive technology platform that combines novel disease models with robust human genetics to identify novel targets. These discoveries are then validated with a range of systems biology approaches and evaluated in terms of drugability. The company's target discovery and validation approach is based on:

  • A unique DNA collection of worldwide population groups (>44,000 samples);
  • Validated animal model systems for diabetes/obesity and depression/anxiety;
  • A 1400 CPU parallel Linux cluster supercomputer for statistical analysis of genetic data;
  • The eXpress Technology Platform, a proprietary research engine for rapid target discovery and validation for any disease.

    ChemGenex has identified genes whose protein products have potential as suitable therapeutics, have disease associations and are protected by an intellectual property position. Using animal models in both diabetes and obesity the company is currently evaluating the activity of proteins and small molecules as potential human therapeutics in conjunction with Merck KGaA. ChemGenex is also collaborating with Vernalis in the areas of anxiety and depression.

    Date Established: 2004 (formed by a merger)

    Other Company Location:

    3475 Edison Way, Suite M
    Menlo Park, California 94025 U.S.A.
    Phone: 650-474-9800 Fax: 650-474-9808

    Last Updated: 11-09-04

    Key Statistics

    Ownership: Public

    Web Site: ChemGenex Pharmaceuticals Limited
    Employees: 60
    Symbol: CXS.AX

  • Industry


    Merck KGaA  Discovery and development collaboration in diabetes and obesity.

    Vernalis  Discovery and development collaboration in anxiety and depression.

    Company News
    Cephalon, Inc. (CEPH) Lodges Bidder's Statement for A$167 Million Offer for ChemGenex Pharmaceuticals Limited (CXS.AX) 4/13/2011 7:00:20 AM
    Cephalon, Inc. (CEPH) Offers To Buy Rest Of Australia's ChemGenex Pharmaceuticals Limited (CXS.AX) For $163M 3/29/2011 6:59:29 AM
    ChemGenex Pharmaceuticals Limited (CXS.AX) Presents Updated Analysis at American Society of Hematology on OMAPRO(TM) in CML Patients Who Failed Two or Three Approved TKI Drugs 12/6/2010 11:13:23 AM
    LifeSci Advisors, LLC (LSA) Announces Investment Opinion on ChemGenex Pharmaceuticals Limited (CXS.AX) 10/7/2010 9:50:05 AM
    ChemGenex Pharmaceuticals Limited (CXS.AX) Completes pre-NDA Meeting with U.S. FDA and Clarifies Timing for Second New Drug Application for OMAPROTM 10/5/2010 12:25:49 PM
    ChemGenex Pharmaceuticals Limited (CXS.AX) and U.S. FDA Agree on Potential Regulatory Pathway for OMAPRO(TM) 7/14/2010 8:43:24 AM
    ChemGenex Pharmaceuticals Limited (CXS.AX) Announces Positive Safety Data on OMAPR(TM) Presented at American Society of Clinical Oncology 6/7/2010 11:50:19 AM
    ChemGenex Pharmaceuticals Limited (CXS.AX) to Host Investor Briefing 5/4/2010 9:47:40 AM
    ChemGenex Pharmaceuticals Limited (CXS.AX) Receives a Complete Response Letter from the FDA for OMAPRO(TM) 4/12/2010 9:30:44 AM
    FDA's Oncologic Drug Advisory Committee Recommends ChemGenex Pharmaceuticals Limited (CXS.AX) Validate a Diagnostic Prior to Approval of OMAPRO in Chronic Myeloid Leukemia Patients with T315I Mutation 3/23/2010 7:08:13 AM